Trevi Therapeutics Files 8-K: Shareholder Vote & Financials
Ticker: TRVI · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1563880
Sentiment: neutral
Topics: corporate-governance, financials, filing
TL;DR
Trevi Therapeutics filed an 8-K for shareholder votes and financials. Keep an eye on this.
AI Summary
On June 13, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders and also includes financial statements and exhibits. No specific details regarding the vote or financial performance were provided in the excerpt.
Why It Matters
This filing signals important corporate actions, including potential shareholder decisions and the release of financial information, which are crucial for investors to assess the company's direction and health.
Risk Assessment
Risk Level: medium — 8-K filings often precede significant corporate events or disclosures that can impact stock price, requiring investor attention.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- June 13, 2024 (date) — Date of report
FAQ
What specific matters are being submitted to a vote of Trevi Therapeutics' security holders?
The provided excerpt of the 8-K filing does not specify the exact matters to be voted on by security holders.
What are the key financial statements and exhibits included in this 8-K filing?
The excerpt states that financial statements and exhibits are included, but does not detail their content or specific financial figures.
Has Trevi Therapeutics' principal executive office address changed recently?
The filing lists the current principal executive offices at 195 Church Street, 16th Floor, New Haven, Connecticut 06510, and does not indicate a recent change.
What is Trevi Therapeutics' IRS Employer Identification Number?
Trevi Therapeutics, Inc.'s IRS Employer Identification Number is 45-0834299.
What is the Commission File Number for Trevi Therapeutics?
The Commission File Number for Trevi Therapeutics, Inc. is 001-38886.
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-06-13 17:01:16
Key Financial Figures
- $0.001 — e on which registered Common stock, $0.001 par value per share TRVI The Nasdaq
Filing Documents
- trvi-20240613.htm (8-K) — 59KB
- 0000950170-24-073129.txt ( ) — 177KB
- trvi-20240613.xsd (EX-101.SCH) — 28KB
- trvi-20240613_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On June 13, 2024, Trevi Therapeutics, Inc., a Delaware corporation (the "Company"), held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the following proposals: 1. The following nominees were elected to the Board of Directors of the Company as Class II directors for terms expiring at the 2027 annual meeting of stockholders. For Withheld Broker Non-Votes Dominick Colangelo 47,134,746 104,348 6,825,772 Edward Mathers 32,688,731 14,202,702 7,173,433 David Meeker, M.D. 33,561,857 13,329,576 7,173,433 2. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024 was ratified. For: 54,024,710 Against: 26,391 Abstain: 13,765
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREVI THERAPEUTICS, INC. Date: June 13, 2024 By: /s/ Lisa Delfini Name: Lisa Delfini Title: Chief Financial Officer